A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer
about
GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patientsGuanylyl cyclase C as a biomarker in colorectal cancerLineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer.Selection of optimal reference genes for normalization in quantitative RT-PCR.Previstage GCC test for staging patients with colorectal cancer.Colorectal cancer immunotherapy.Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.Current status of gene expression profiling to assist decision making in stage II colon cancerEvaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancerGUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancerOccult tumor burden predicts disease recurrence in lymph node-negative colorectal cancerBacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics.Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.Molecular staging individualizing cancer management.Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer.A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients.Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine.GUCY2C molecular staging personalizes colorectal cancer patient managementEvidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions.Molecular staging of node negative patients with colorectal cancer.Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells.Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cellsGuanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancerExpression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?Can colorectal cancer be prevented or treated by oral hormone replacement therapy?Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor.Cure and curse: E. coli heat-stable enterotoxin and its receptor guanylyl cyclase CLymph node CEA and MUC2 mRNA as useful predictors of outcome in colorectal cancer.The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.STa peptide analogs for probing guanylyl cyclase C.Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells.Expression of guanylyl cyclase C in tissue samples and the circulation of rectal cancer patients.
P2860
Q24641833-3BB9A80A-85B3-4ED9-98B1-6BC550522753Q27011759-CF436D97-2661-4A6E-8CBA-EB9A20DE0B18Q30488671-2561BD85-96EF-4BF3-8AD7-87D86392CB79Q30490467-28AC2FB9-39FA-43DD-8188-D13F0A9D2383Q33427566-46D25BA2-EB02-42F6-9475-5A8918326028Q33578372-C8FCF3DF-1D23-4B9F-95DE-FEA600950671Q33641600-D0AECCCD-9496-4857-8E6F-981F18E1F457Q33701465-FB5B8C39-E789-4A1A-B3C7-C5AF38E343C3Q33722761-EB41032C-3BAE-4F94-B347-9060477571A1Q33829763-0C658653-3CFD-4C9E-8D92-9C6D7825E4B8Q33887066-F40BE338-8465-44C8-9F36-26F68DAFEBD3Q34458591-A094F1AF-41E3-4FF2-9ECD-8D00F85545B7Q34619403-2FA625B1-FF15-4E38-BF77-21466DC65175Q34988050-86B8774C-7506-4ED4-8356-56125061A7CFQ35155933-107CF641-13E2-4E03-A6B4-9EF6C12E3F32Q35605899-B5D9D888-8E0D-4946-9A21-08B10655C726Q35854173-2535FA60-4F1E-4DBF-8B23-40CF32B5DA0BQ36016596-BD31E20B-9E82-4205-BDDC-84F5F028562EQ36156776-4058C27B-8207-400E-BD4E-9D68FA21520EQ36202841-A3A31081-C221-43F7-A194-9EA4F4EFEDE7Q36336227-59015E7F-27B5-478F-85FF-C54365FCC3B3Q36646520-C395CD67-1852-4AFE-9319-C180DCD8EBAAQ36646525-3908D633-8A21-402C-848F-EB7D4BF8B6C8Q36677474-41B4F1C9-ECAB-4925-A2B4-324FA9D5DE3AQ36838038-DE23A379-4971-434C-9D0C-FA640FEE5A84Q37208825-CB2AE843-26FA-4D07-B9DA-A10F36946A47Q37337701-F2ED5706-A7A8-459A-A69E-D89FE2178CDCQ37372472-DEF427E5-D7B4-433F-8B48-65C26D87B03AQ37463792-DDF72E5A-10D9-4F60-A5D4-709C72C51F05Q37486782-08D0F7EC-4595-4584-B568-5CAFE42923B2Q37601318-BF5F2858-AB1A-4D8C-A12F-A18EB9443489Q37659196-C21F2849-E099-405A-8CE5-AEEA234E03DBQ37666685-68E16E89-6EE1-4BA3-8294-22BCD6D37C4CQ37783622-F0374D6B-C035-4723-BAF2-C281DD28D5BFQ37954322-13685D17-6940-4BBA-B6C5-CD733D0AEA58Q39535135-539A614F-4319-4230-84B4-5B77D2B8DE87Q39802240-3629CA02-70C6-4C0B-AC37-066A0167E9B3Q39963192-C1B9F9DF-FAFA-43C4-AD2D-F005C3D98B77Q40274361-5C0308DC-6C95-4B90-8806-E00DADEA7706Q40971199-187FF18A-5793-41F3-A779-9877A437202B
P2860
A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A validated quantitative assay ...... atients with colorectal cancer
@ast
A validated quantitative assay ...... atients with colorectal cancer
@en
A validated quantitative assay ...... atients with colorectal cancer
@nl
type
label
A validated quantitative assay ...... atients with colorectal cancer
@ast
A validated quantitative assay ...... atients with colorectal cancer
@en
A validated quantitative assay ...... atients with colorectal cancer
@nl
prefLabel
A validated quantitative assay ...... atients with colorectal cancer
@ast
A validated quantitative assay ...... atients with colorectal cancer
@en
A validated quantitative assay ...... atients with colorectal cancer
@nl
P2093
P3181
P1476
A validated quantitative assay ...... atients with colorectal cancer
@en
P2093
Christine Bonaccorso
David Weinberg
Janis Haaf
Juan Palazzo
Karl Nielsen
Matthew E Witek
Stephanie Schulz
Terry Hyslop
P304
P3181
P356
10.1158/1078-0432.CCR-06-0865
P407
P577
2006-08-01T00:00:00Z